A method for analyzing related substances of Vernakalant
Through high performance liquid chromatography, the separation of the A4 enantiomer of Venacalan hydrochloride intermediate was solved by using cellulose-tris(3,5-dichlorophenylcarbamate) chiral column and specific mobile phases. The problem has achieved rapid and accurate separation, improving drug quality control and clinical safety.
Patent Information
- Application Number
- CN202111261807.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-10-28
AI Technical Summary
Existing methods are difficult to effectively detect and isolate enantiomers of Venacalan Hydrochloride intermediate A4, resulting in challenges in drug quality control and clinical use.
Using high performance liquid chromatography, a mixed solvent of cellulose-tris(3,5-dichlorophenylcarbamate) chiral column and n-hexane-anhydrous ethanol-trifluoroacetic acid was used as the mobile phase, and the flow was optimized. The phase composition ratio and flow rate can achieve effective separation of Venacalan intermediate A4 and its enantiomers.
The rapid and accurate separation of the A4 enantiomer of the Venacalan intermediate was achieved, which improved the reliability of drug purity control and pharmacokinetic research, and ensured the clinical safety of the drug.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to a high performance liquid chromatography method, in particular to a chiral separation method for separating enantiomers of a Vernakalant hydrochloride intermediate, and belongs to the field of chemical analysis. Background Art
[0002] Vernakalant hydrochloride, [CAS: 748810-28-8 chemical name (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-3-pyrrolidinol hydrochloride], chemical structure is as follows:
[0003]
[0004] Vernakalant is a new type of atrial selective Class III antiarrhythmic drug. It was jointly developed by Canadian CardionmePharma and American Astellas Pharma. Its mechanism of action is to selectively block the sodium and potassium (IKur) ion channels of the atrium during the onset of atrial fibrillation. Inhibition of IKur current can prolong the duration of the atrial action potential and reduce the risk of arrhythmia. From the existing data, it shows good effectiveness and safety in converting newly-occurring atrial fibrillation, and its efficacy is better than amiodarone. It is clinically used to treat atrial fibrillation.
[0005] Vernakalant and its intermediates can be synthesized by methods disclosed in the literature:
[0006]
[0007] Vernakalant and its intermediate A4 have multiple chiral carbon atoms and exist in multiple enantiomers. Due to different cell expressions, the enantiomers of Vernakalant hydrochloride have significant differences in pharmacokinetics. The effective detection or separation and removal of its enantiomers is a difficult point in quality control during the research and development of Vernakalant. Therefore, it is of great application value to establish a good high-performance liquid chromatography method for separating the enantiomers of Vernakalant or intermediates. First, it provides a basis for the improvement of the process of synthesis, separation and purification; second, it provides a basis for the quality of preparations; third, it is used to explore the transformation or metabolic rules of enantiomers in animals or humans, and provide a basis for rational clinical drug use.
[0008] To date, there are no reports in the literature on the separation or detection of optical isomers of Vernakalant or its intermediates.
[0009] Vernakalan intermediate A4 is shown in formula (III). Due to the presence of a chiral center, there are multiple enantiomers. One of the optical isomers is shown in formula (IV). Due to the similar structure, it is very difficult to detect and separate.
[0010]
[0011] In the process of drug development, in order to ensure the safety and effectiveness of drugs, it is necessary to study, detect and monitor the impurities in drug raw materials and their preparations. The adverse reactions caused by drugs during clinical use are not only related to the pharmacological activity of the main ingredients, but also closely related to the influence of impurities. In order to ensure the safe use of drugs in clinical practice, the impurity content in drugs must be strictly controlled. Summary of the invention
[0012] The inventor of the present patent application has discovered a high performance liquid chromatography method that can effectively separate the enantiomers of the Vernakalant intermediate A4. The method of the present invention is simple to operate, low in cost, and can simply, quickly and accurately separate the enantiomers of the Vernakalant intermediate A4.
[0013] The object of the present invention is to provide a high performance liquid chromatography method for separating the enantiomers of Vernakalant intermediate A4 simply and quickly, thereby achieving effective separation and accurate determination of the corresponding isomers of Vernakalant intermediate A4 shown in formula (III) and Vernakalant intermediate A4 shown in formula (IV).
[0014] Specifically, in one embodiment of the present invention, a method for analyzing Vernakalant-related substances is provided, characterized in that the substance to be tested is eluted in a fiber-type chiral column by high performance liquid chromatography; the fiber-type chiral column is preferably a cellulose-tris(3,5-dichlorophenylcarbamate) chiral column;
[0015] The test substance is a compound comprising the following formula (I) and / or its enantiomer formula (II):
[0016]
[0017] wherein R is independently selected from a hydrogen atom, a C 1-3 Alkyl, C 1-3 Alkoxy, hydroxyl, amino, thiol, carbonyl, aldehyde, carboxyl, nitro, cyano, ester, amide, halogen, C 1-3 Haloalkyl, sulfonyl, sulfonic acid, quaternary ammonium;
[0018] Preferably, the test substance is a Vernakalant intermediate A4 of formula (III) and / or an enantiomer of Vernakalant intermediate A4 of formula (IV):
[0019]
[0020] In one embodiment provided by the present invention, a method for analyzing Vernakalant-related substances uses a mixed solvent of n-hexane-alcohol solvent-acid solvent as the mobile phase, and the alcohol solvent is selected from one or more of anhydrous methanol, anhydrous ethanol, ethanol-isopropanol, and isopropanol; preferably anhydrous ethanol; the acid solvent is selected from one or more of glacial acetic acid, trifluoroacetic acid, and formic acid, preferably trifluoroacetic acid.
[0021] In one embodiment provided by the present invention, the cellulose-tris(3,5-dichlorophenylcarbamate) chiral column is DAICEL IC-3, preferably, the DAICEL The length of IC-3 is 50 mm to 300 mm, and more preferably, 250 mm; The particle size of IC-3 is 1 μm to 10 μm, preferably 3 μm; more preferably, the DAICEL IC-3 is 4.6mm×250mm, 3μm.
[0022] In one embodiment provided by the present invention, the volume ratio of the mixed solvent of n-hexane-alcohol solvent-acid solvent as the mobile phase is 85:15:0.08~95:5:0.5; preferably 85:15:0.08~95:5:0.12, and further preferably 85:15:0.1~95:5:0.1; the flow rate is 0.5~1.2ml / min, further preferably 0.8~1.1ml / min, and most preferably 1.0ml / min.
[0023] In one embodiment provided by the present invention, the mixed solvent of n-hexane-alcohol solvent-acid solvent is a mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid as the mobile phase; the volume ratio of the mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid is 86:14:0.1; and / or the flow rate is 1.0 mL / min.
[0024] There is no prior art report on the separation of Vernakallan intermediate A4 and its enantiomers. The present invention has found through a large number of experimental explorations that it is difficult to achieve complete separation of Vernakallan intermediate A4 and its enantiomers and obtain good peak shapes using chiral separation columns with conventional fillers, especially when the running time of the method is short, the complete separation of enantiomers is more difficult. Furthermore, under the conditions of the specific chiral separation column used in the present invention, if the mobile phase composition and ratio are not within the selected range, it is also difficult to effectively separate, which fully demonstrates that the present invention has obvious specificity in its selection.
[0025] In one embodiment provided by the present invention, a method for separating and quantifying the enantiomers of Vernakalant intermediate A4 by high performance liquid chromatography is provided, comprising the following steps:
[0026] (1) Take an appropriate amount of Vernakallan intermediate A4 sample, dissolve it in mobile phase and quantitatively dilute it to prepare a test solution containing about 0.2 mg of Vernakallan intermediate A4 sample per 1 ml; accurately measure 1 ml of the test solution, place it in a 100 ml volumetric flask, add mobile phase to dilute to the scale, shake well, and use it as the control solution.
[0027] (2) setting the mobile phase flow rate to 0.5-1.2 ml / min, preferably 1.0 ml / min, the detection wavelength to 210±2 nm, preferably 210 nm, and the column temperature to 25-35° C., preferably 30° C.;
[0028] (3) Take 10 μl of the sample solution in step (1) and inject it into a liquid chromatograph to record the chromatogram.
[0029] Wherein, the liquid chromatograph is a high performance liquid chromatograph, and a Waters e2695 high performance liquid chromatograph can be selected;
[0030] Wherein, the chromatographic column: cellulose-tris(3,5-dichlorophenylcarbamate) chiral column;
[0031] Detection wavelength: 210nm;
[0032] Flow rate: 1.0 mL / min;
[0033] Injection volume: 10 μl.
[0034] The volume ratio of the mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid as the mobile phase is 85:15:0.08-95:5:0.12, preferably 86:14:0.1. The flow rate is preferably 0.5-1.2 ml / min, and most preferably 1.0 ml / min.
[0035] The present invention selects a specific separation column and mobile phase, and selects the flow rate, column temperature, and the composition ratio of the mobile phase, so that the overall separation effect of the present invention is particularly better.
[0036] The beneficial effects of the present invention compared to the prior art include:
[0037] (1) Using cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL IC-3, 4.6 mm × 250 mm, 3 μm), which can effectively separate the enantiomers of the Vernakalant intermediate A4;
[0038] (2) Selecting a mobile phase to dissolve the sample, the volume ratio of the mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid as the mobile phase is 85:15:0.08-95:5:0.12, which improves the peak shape of the chromatographic peak; selecting an injection volume of 10 μl and a column temperature of 30°C to improve the symmetry of the chromatographic peak. The present invention solves the problem of separating the enantiomers of the Vernakalant intermediate A4, which is of great significance to drug metabolism research, chiral impurities, purity control and many other aspects.
[0039] (3) Selecting a mobile phase to dissolve the sample, the volume ratio of the mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid as the mobile phase is 86:14:0.1. Under the optimal conditions, the optimal separation of the Vernakalant intermediate A4 enantiomer is achieved in a very short time (20 minutes). BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 This is the chromatogram of Vernakalant intermediate A4;
[0041] Figure 2 It is the chromatogram of the A4 enantiomer of the Vernakalant intermediate;
[0042] Figure 3 It is the chromatogram of the test solution of the sample of Vernakalant intermediate A4;
[0043] Figure 4 It is the chromatogram of the test solution under the chromatographic conditions of Example 2;
[0044] Figure 5 It is the chromatogram of the test solution under the chromatographic conditions of Example 3;
[0045] Figure 6 It is the chromatogram of the test solution under the chromatographic conditions of Example 4;
[0046] Figure 7 It is the chromatogram of the test solution under the chromatographic conditions of Example 5;
[0047] Figure 8 It is the chromatogram of the test solution under the chromatographic conditions of Control Example 1;
[0048] Fig. 9 It is the chromatogram of the test solution under the chromatographic conditions of Control Example 2; DETAILED DESCRIPTION
[0049] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description progresses. However, the embodiments are merely exemplary and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and small tests of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.
[0050] Development process: During the initial stage of method development, when screening chromatographic columns, we found that the chromatographic column DAICEL IC-3, 4.6mm×250mm, 3μm has a separation effect on intermediate A4 and its enantiomers, so it was further optimized on the chromatographic column IC-3, 4.6mm×250mm, 3μm. When n-hexane: isopropanol: trifluoroacetic acid (80:20:0.1) was used as the mobile phase for isocratic elution, intermediate A4 and its enantiomers could be clearly separated, but the unknown impurity peak in the test solution easily interfered with the A4 isomer. After adjusting the isopropanol ratio in the mobile phase, it was found that: when the isopropanol ratio increased, the unknown impurity peak appeared before the peak of the A4 isomer; when the isopropanol ratio decreased, the unknown impurity peak appeared after the peak of the A4 isomer. Therefore, the separation degree was increased by lowering the mobile phase ratio, but the expected effect was not achieved in the end. Taking into account the phenomenon that the impurity peak appears before the peak of the A4 isomer when the proportion of isopropanol increases (when the polarity of the mixed solution increases), an attempt was made to elute the impurity peak before the A4 isomer. Therefore, isopropanol was replaced with ethanol with a higher polarity. By adjusting the mobile phase ratio and flow rate, the method was finally determined to use n-hexane: ethanol: trifluoroacetic acid (86:14:0.1) as the mobile phase; the detection wavelength was 210 nm; the column temperature was 30°C; and the flow rate was 1.0 ml / min.
[0051] Example 1
[0052] Instrument and conditions: Waters e2695 HPLC
[0053] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0054] IC-3, 4.6mm×250mm, 3μm);
[0055] The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid was 86:14:0.1;
[0056] Detection wavelength: 210nm;
[0057] Column temperature: 30°C;
[0058] Flow rate: 1.0ml / min;
[0059] Injection volume: 10 μl.
[0060] Experimental steps:
[0061] Vernakallan intermediate A4: Accurately weigh an appropriate amount of Vernakallan intermediate A4 reference substance, dissolve it in mobile phase, and dilute it with mobile phase to a solution containing about 2 μg per 1 ml. Accurately measure 10 μl and inject it into the chromatograph to record the chromatogram. The chromatogram of Vernakallan intermediate A4 is shown in Figure 1 , the peak is at 17.098min.
[0062] Vernakallan intermediate A4 enantiomer: Accurately weigh an appropriate amount of the enantiomer of Vernakallan intermediate A4, dissolve it in the mobile phase, and dilute it with the mobile phase to a solution containing 10 μg per 1 ml. The chromatogram of the Vernakallan intermediate A4 enantiomer is shown in Figure 2 , the peak is at 14.778min.
[0063] Test solution: Accurately weigh an appropriate amount of Vernakallan intermediate A4 sample, dissolve it in mobile phase, and dilute it with mobile phase to a solution containing about 0.2 mg per 1 ml. The chromatogram of the Vernakallan intermediate A4 sample is shown in Figure 3 In the figure, peak 1 is the enantiomer of A4, with a retention time of 14.843min; peak 2 is the Vernakallan intermediate A4, with a retention time of 17.155min. The A4 isomer, the unknown impurity peak and the Vernakallan intermediate A4 are completely separated, with a separation degree of 2.0 and 2.4 respectively, and the symmetry is good. Under the chromatographic conditions, the Vernakallan intermediate A4 and its enantiomer can be completely separated, and can also be well separated from the unknown impurity peak; the isomer content can be accurately quantified by the external standard method or the self-control method.
[0064] Example 2
[0065] Instrument and conditions: Waters e2695 HPLC
[0066] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0067] IC-3, 4.6mm×250mm, 3μm);
[0068] The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid is 85:15:0.1;
[0069] Detection wavelength: 210nm;
[0070] Column temperature: 30°C;
[0071] Flow rate: 1.0ml / min;
[0072] Injection volume: 10 μl.
[0073] Test steps and results:
[0074] Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 4 The peak times of Vernakalant intermediate A4 and its isomers were 15.571min and 14.155min, respectively, with a separation degree of 3.0 and good symmetry. Under this chromatographic condition, Vernakalant intermediate A4 and its enantiomers were completely separated.
[0075] Example 3
[0076] Instrument and conditions: Waters e2695 HPLC
[0077] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0078] IC-3, 4.6mm×250mm, 3μm);
[0079] The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid was 95:5:0.1;
[0080] Detection wavelength: 210nm;
[0081] Column temperature: 30°C;
[0082] Flow rate: 1.0ml / min;
[0083] Injection volume: 10 μl.
[0084] Test steps and results:
[0085] Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 5 The peak times of Vernakalant intermediate A4 and its isomers were 44.211min and 36.910min, respectively, with a separation degree of 5.7 and good symmetry. Under this chromatographic condition, Vernakalant intermediate A4 and its enantiomers were completely separated.
[0086] Example 4
[0087] Instrument and conditions: Waters e2695 HPLC
[0088] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0089] IC-3, 4.6mm×250mm, 3μm);
[0090] The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid is 90:10:0.10;
[0091] Detection wavelength: 210nm;
[0092] Column temperature: 30°C;
[0093] Flow rate: 1.0ml / min;
[0094] Injection volume: 10 μl.
[0095] Test steps and results:
[0096] Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 6 The peak times of Vernakalant intermediate A4 and its isomers were 28.358min and 23.886min, respectively, with a separation degree of 5.5 and good symmetry. Under this chromatographic condition, Vernakalant intermediate A4 and its enantiomers were completely separated.
[0097] Example 5
[0098] Instrument and conditions: Waters e2695 HPLC
[0099] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0100] IC-3, 4.6mm×250mm, 3μm);
[0101] The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid is 85:15:0.1;
[0102] Detection wavelength: 210nm;
[0103] Column temperature: 30°C;
[0104] Flow rate: 0.5ml / min;
[0105] Injection volume: 10 μl.
[0106] Test steps and results: Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 7 The elution times of the intermediate A4, unknown impurity peak and A4 isomer were 31.433min, 28.424min and 27.330min, respectively, with separation degrees of 1.5 and 3.5, respectively, and good symmetry. Under this chromatographic condition, the intermediate A4 and its enantiomers were completely separated.
[0107] Comparative Example 1:
[0108] Instrument and conditions: Waters e2695 HPLC
[0109] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0110] IG, 4.6 mm × 250 mm, 5 μm) mobile phase volume ratio: n-hexane-anhydrous ethanol-trifluoroacetic acid ratio was 86:14:0.1;
[0111] Detection wavelength: 210nm;
[0112] Column temperature: 30°C;
[0113] Flow rate: 1.0ml / min;
[0114] Injection volume: 10 μl.
[0115] Test steps and results: Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 8 As can be seen from the spectrum, the two substances are not completely separated. Under the chromatographic conditions, they cannot be effectively separated, and it is even more impossible to accurately quantify the content of their isomers.
[0116] Comparative Example 2
[0117] Instrument and conditions: Waters e2695 HPLC
[0118] Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL
[0119] IC-3, 4.6mm×250mm, 3μm);
[0120] The volume ratio of the mobile phase: n-hexane-anhydrous ethanol-diethylamine is 86:14:0.1;
[0121] Detection wavelength: 210nm;
[0122] Column temperature: 30°C;
[0123] Flow rate: 1.0ml / min;
[0124] Injection volume: 10 μl.
[0125] Test steps and results: Accurately measure 10 μl of the test solution, inject it into the liquid chromatograph, and record the chromatogram. Fig. 9. As can be seen from the spectrum, the response of Vernakallan intermediate A4 and its corresponding isomers under this chromatographic condition is low, and the baseline noise is large. The spectral peak of Vernakallan intermediate A4 isomer is not seen in the system suitability solution. Increasing the concentration will lead to a wider spectral peak and a worse peak shape. Under this chromatographic condition, the two cannot be effectively separated, and it is even more impossible to accurately quantify the content of their isomers.
[0126] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for analyzing related substances of Vernakalant, characterized in that: High performance liquid chromatography is used, with a mixed solvent of n-hexane-alcohol solvent-acid solvent as the mobile phase, and the analyte is eluted in a fiber chiral column; Wherein, the alcohol solvent is anhydrous ethanol; the acid solvent is trifluoroacetic acid; the volume ratio of the mixed solvent of n-hexane-alcohol solvent-acid solvent as the mobile phase is 85:15:0.08 to 95:5:0.5; The fiber-type chiral column is a cellulose-tris (3,5-dichlorophenyl carbamate) chiral column DAICEL The test substance is an enantiomer of the Vernakalant intermediate A4 of formula (III) and / or the Vernakalant intermediate A4 of formula (IV):
2. The method according to claim 1, characterized in that The DAICEL The length is 50mm~300mm; the flow rate is 0.5~1.2ml / min.
3. The method according to claim 2, characterized in that: Said The particle size is 1 μm to 10 μm; the volume ratio of the mixed solvent of n-hexane-alcohol solvent-acid solvent as the mobile phase is 85:15:0.08 to 95:5:0.12; and the flow rate is 0.8 to 1.1 ml / min.
4. The method according to claim 3, characterized in that The mobile phase is a mixed solvent of n-hexane-anhydrous ethanol-trifluoroacetic acid; the volume ratio of n-hexane:anhydrous ethanol:trifluoroacetic acid is 86:14:0.1; the flow rate is 1.0 mL / min.
5. The method according to any one of claims 1 to 4, characterized in that: The following steps are included: (1) Take an appropriate amount of Vernakallan intermediate A4 sample, dissolve it in mobile phase and quantitatively dilute it to prepare a test solution containing about 0.2 mg of Vernakallan intermediate A4 sample per 1 ml; accurately measure 1 ml of the test solution, place it in a 100 ml volumetric flask, add mobile phase to dilute to the scale, shake well, and use it as a control solution; (2) Set the mobile phase flow rate to 0.5-1.2 ml / min, the detection wavelength to 210 ± 2 nm, and the column temperature to 25-35 °C; (3) Take 10 μl of the sample solution in step (1) and inject it into a liquid chromatograph to record the chromatogram.
6. The method according to claim 5, characterized in that In the step (2), the mobile phase flow rate is set to 1.0 ml / min, the detection wavelength is set to 210 nm, and the column temperature is set to 30°C.
7. The method according to claim 1, characterized in that The analysis method is, Instruments and conditions: Waters e2695 high performance liquid chromatograph; Chromatographic column: Cellulose-tris((3,5-dichlorophenylcarbamate) chiral column DAICEL 4.6mm×250mm, 3μm; The volume ratio of the mobile phase: hexane-anhydrous ethanol-trifluoroacetic acid was 86:14:0.1; Detection wavelength: 210nm; Column temperature: 30°C; Flow rate: 1.0ml / min; Injection volume: 10 μl.
